Moderna, Inc. has announced that five of its abstracts focusing on investigational mRNA therapeutics will be presented at the upcoming 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The congress is scheduled to take place from September 2-6, 2025, at the Kyoto International Conference Center in Kyoto, Japan. This event marks a significant opportunity for the company to share its latest research findings with the global scientific community.
Among the accepted presentations, Moderna will deliver three oral talks and two poster presentations. These will cover the company’s research on propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a). Notably, this will be the first time Moderna showcases data related to MMA and GSD1a at a scientific congress.
Details of the Presentations
The abstracts accepted for presentation include detailed findings that could enhance understanding of these metabolic disorders. The oral presentations will provide insights into the mechanisms and potential therapeutic applications of Moderna’s mRNA technology in treating these inborn errors of metabolism.
The two poster presentations will complement the oral sessions by offering a more detailed exploration of the research findings. This format allows for direct engagement with attendees, fostering discussions that could lead to collaborative opportunities and new insights in the field.
Moderna’s focus on mRNA therapeutics represents a transformative approach in treating genetic disorders. The company’s innovative research aligns with the growing interest in mRNA technology, particularly following its successful applications in vaccines.
As the congress draws nearer, the scientific community is keenly anticipating the information Moderna will present. The ICIEM serves as a crucial platform for experts in the field to exchange knowledge and advance research on inborn errors of metabolism, ultimately aiming to improve patient outcomes.
The acceptance of these abstracts not only underscores the progress Moderna has made in its research programs but also highlights the potential of mRNA technology to address previously unmet medical needs. By participating in this prestigious event, Moderna continues to position itself at the forefront of innovation in the biopharmaceutical industry.
